Ocugen (OCGN) Cash & Current Investments (2014 - 2025)
Ocugen (OCGN) reported Cash & Current Investments of $37.8 million for Q1 2025, up 43.18% on a YoY basis from $26.4 million in Q1 2024, and up 140.81% quarter-over-quarter from $15.7 million in Q2 2024.
Ocugen (OCGN) Cash & Current Investments (2014 - 2025) Analysis & Trends
Ocugen has reported Cash & Current Investments for 12 years, with the latest figure at $37.8 million in Q1 2025.
- For the quarter ending Q1 2025, Cash & Current Investments rose 43.18% year-over-year to $37.8 million; the trailing twelve-month figure through Mar 2025 stood at $37.8 million (up 43.18% YoY), and the FY2023 full-year result was $39.5 million, down 56.6% from the prior year.
- Cash & Current Investments for Q1 2025 stood at $37.8 million, up from $15.7 million in the prior quarter.
- The five-year high for Cash & Current Investments was $129.8 million in Q1 2022, with the low at $15.7 million in Q2 2024.
- Historically, Cash & Current Investments has averaged $74.7 million across 5 years, with a median of $76.7 million in 2023.
- Annual changes were most pronounced in 2021 — Cash & Current Investments surged 1302.82% — and 2024, when it tumbled 77.76%.
- Ocugen's Cash & Current Investments stood at $95.0 million in 2021, then dropped by 4.24% to $90.9 million in 2022, then slumped by 56.6% to $39.5 million in 2023, then plunged by 60.22% to $15.7 million in 2024, then surged by 140.81% to $37.8 million in 2025.
- The last three Cash & Current Investments figures came in at $37.8 million (Q1 2025), $15.7 million (Q2 2024), and $26.4 million (Q1 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 2.77 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 18.44 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Ocugen | 397.97 Mn | 397.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 37.80 Mn |
| Jun 30, 2024 | 15.70 Mn |
| Mar 31, 2024 | 26.40 Mn |
| Dec 31, 2023 | 39.46 Mn |
| Sep 30, 2023 | 53.48 Mn |
| Jun 30, 2023 | 70.58 Mn |
| Mar 31, 2023 | 76.72 Mn |
| Dec 31, 2022 | 90.93 Mn |
| Sep 30, 2022 | 101.60 Mn |
| Jun 30, 2022 | 115.01 Mn |
| Mar 31, 2022 | 129.77 Mn |
| Dec 31, 2021 | 94.96 Mn |
| Sep 30, 2021 | 107.35 Mn |
| Jun 30, 2021 | 115.64 Mn |
| Mar 31, 2021 | 44.79 Mn |
| Dec 31, 2020 | 24.04 Mn |
| Sep 30, 2020 | 19.11 Mn |
| Jun 30, 2020 | 14.97 Mn |
| Mar 31, 2020 | 3.19 Mn |
| Dec 31, 2019 | 7.44 Mn |